These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 23818351)

  • 1. D-dimer is a marker of response to chemotherapy in patients with metastatic colorectal cancer.
    Inanc M; Er O; Karaca H; Berk V; Ozkan M; Dikilitas M; Elmali F
    J BUON; 2013; 18(2):391-7. PubMed ID: 23818351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CEA and CA19.9 as early predictors of progression in advanced/metastatic colorectal cancer patients receiving oxaliplatin-based chemotherapy and bevacizumab.
    Petrioli R; Licchetta A; Roviello G; Pascucci A; Francini E; Bargagli G; Conca R; Miano ST; Marzocca G; Francini G;
    Cancer Invest; 2012 Jan; 30(1):65-71. PubMed ID: 22236191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy.
    Sun Z; Zhang N
    World J Surg Oncol; 2014 Dec; 12():397. PubMed ID: 25543664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating D-dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma.
    Blackwell K; Hurwitz H; Liebérman G; Novotny W; Snyder S; Dewhirst M; Greenberg C
    Cancer; 2004 Jul; 101(1):77-82. PubMed ID: 15221991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. D-dimer and international normalized ratio (INR) are correlated with tumor markers and disease stage in colorectal cancer patients.
    Kilic L; Yildiz I; Sen FK; Erdem MG; Serilmez M; Keskin S; Ciftci R; Karabulut S; Ordu C; Duranyildiz D; Tas F
    Cancer Biomark; 2015; 15(4):405-11. PubMed ID: 25792472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retrospective cohort study of metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy, with an exploratory analysis of changing serum carcinoembryonic antigen levels.
    Ng SL; Burns WI; Snyder RD; Newnham GM; McLachlan SA; Liew D; Dowling AJ
    Asia Pac J Clin Oncol; 2012 Jun; 8(2):172-9. PubMed ID: 22524576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of tumor growth factor levels during chemotherapy in patients with metastatic colorectal cancer.
    Inanç M; Er O; Karaca H; Berk V; Ozkan M; Saraymen R; Elmalı F
    Med Oncol; 2012 Dec; 29(5):3119-24. PubMed ID: 22580817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gamma-glutamyl transpeptidase level is a novel adverse prognostic indicator in human metastatic colorectal cancer.
    He WZ; Guo GF; Yin CX; Jiang C; Wang F; Qiu HJ; Chen XX; Rong RM; Zhang B; Xia LP
    Colorectal Dis; 2013 Aug; 15(8):e443-52. PubMed ID: 23621885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Folfox4 regimen administered through combined hepatic arterial and systemic infusion for treatment of colorectal cancer with unresectable liver metastases.
    Guan M; Chen SC; Ying HY; Zhao L; Li XY; Zhou JF; Shao YJ; Yang XD; Lin Y; Ning XH; Bai CM
    Chin Med J (Engl); 2012 Oct; 125(20):3640-5. PubMed ID: 23075717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic significance of a D-dimer cut-off level of >3 µg/ml in colorectal cancer patients treated with standard chemotherapy plus bevacizumab.
    Mochizuki S; Yoshino T; Kojima T; Fuse N; Ikematsu H; Minashi K; Yano T; Tahara M; Kaneko K; Doi T; Koike K; Ohtsu A
    Jpn J Clin Oncol; 2010 Oct; 40(10):933-7. PubMed ID: 20494948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Capecitabine and oxaliplatin (XELOX) as first-line treatment for patients with metastatic colorectal cancer.
    Karacetin D; Yalcin B; Okten B; Ozturk S; Maral O; Incekara O
    J BUON; 2009; 14(4):605-8. PubMed ID: 20148449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two Doses of oxaliplatin with capecitabine (XELOX) in metastatic colorectal cancer.
    Moreno-Solórzano I; Ibeas-Rollan R; Monzó-Planella M; Moreno-Solórzano J; Martínez-Ródenas F; Pou-Sanchis E; Hernández-Borlan R; Navarro-Vigo M; Ortigosa-Rodríguez S; Gel-Moreno B
    Clin Colorectal Cancer; 2007 Sep; 6(9):634-40. PubMed ID: 17945035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
    Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
    Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome of patients with colorectal liver metastasis: analysis of 1,613 consecutive cases.
    Dexiang Z; Li R; Ye W; Haifu W; Yunshi Z; Qinghai Y; Shenyong Z; Bo X; Li L; Xiangou P; Haohao L; Lechi Y; Tianshu L; Jia F; Xinyu Q; Jianmin X
    Ann Surg Oncol; 2012 Sep; 19(9):2860-8. PubMed ID: 22526903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers.
    Guadagni F; Kantor J; Aloe S; Carone MD; Spila A; D'Alessandro R; Abbolito MR; Cosimelli M; Graziano F; Carboni F; Carlini S; Perri P; Sciarretta F; Greiner JW; Kashmiri SV; Steinberg SM; Roselli M; Schlom J
    Cancer Res; 2001 Mar; 61(6):2523-32. PubMed ID: 11289125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic arterial infusion of oxaliplatin and L-folinic acid-modulated 5-fluorouracil for colorectal cancer liver metastases.
    Neyns B; Van Nieuwenhove Y; Aerts M; Fontaine C; Vermeij J; Schallier D; Decoster L; De Mey J; Vandenbroucke F; Hoorens A; Delvaux G; De Gréve J
    Anticancer Res; 2006; 26(1B):611-9. PubMed ID: 16739329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective pilot study to assess neoadjuvant chemotherapy for unresectable peritoneal carcinomatosis from colorectal cancer.
    Hompes D; Aalbers A; Boot H; van Velthuysen ML; Vogel W; Prevoo W; van Tinteren H; Verwaal V
    Colorectal Dis; 2014 Aug; 16(8):O264-72. PubMed ID: 24433532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study.
    Waddell T; Gollins S; Soe W; Valle J; Allen J; Bentley D; Morris J; Lloyd A; Swindell R; Taylor MB; Saunders MP
    Cancer Chemother Pharmacol; 2011 May; 67(5):1111-7. PubMed ID: 20676676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of CA19.9 in predicting bevacizumab efficacy for metastatic colorectal cancer patients.
    Formica V; Massara MC; Portarena I; Fiaschetti V; Grenga I; Del Vecchio Blanco G; Sileri P; Tosetto L; Skoulidis F; Pallone F; Roselli M
    Cancer Biomark; 2009; 5(4):167-75. PubMed ID: 19729826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between TBARS levels and glycolytic enzymes: the importance to the initial evaluation of clinical outcome of colorectal cancer patients.
    Farias IL; Farias JG; Rossato L; Araújo MC; Chiesa J; Morsh V; Schetinger MR
    Biomed Pharmacother; 2011 Sep; 65(6):395-400. PubMed ID: 21715128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.